Simulations Plus, Inc. - SLP STOCK NEWS

Simulations Plus and the University of Southern California have secured an NIH grant to develop new AI drug discovery offerings. The partnership aims to advance ligand-based virtual screening by incorporating water-ligand interactions into drug design and optimization activities.

The project will integrate USC's WATGEN algorithm for predicting water positions with Simulations Plus's ADMET Predictor platform. Machine learning approaches will be applied to predict pharmacophore features for 3D shape and feature matching. The goal is to create a first-of-its-kind LBVS solution that enhances current methods and accelerates the discovery of more effective drugs.

The team will validate the technology by designing drugs against defined targets, synthesizing and testing selected compounds experimentally. This collaboration between industry and academia aims to reduce the Design-Make-Test-Analyze cycle of drug discovery significantly.

Simulations Plus (Nasdaq: SLP), a leading provider of biosimulation and medical communications solutions for the biopharma industry, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 6, 2024, at the Marriott Marquis in New York.

CEO Shawn O'Connor will represent the company, hosting one-on-one and small group meetings throughout the day. This prestigious conference is expected to feature over 200 companies and attract a prominent group of investors, including chief investment officers, portfolio managers, and analysts.

The conference provides an excellent opportunity for Simulations Plus to showcase its innovative solutions and network with key industry players and investors. For those interested in learning more about the event, additional information can be found on the Morgan Stanley conference website.

Simulations Plus (Nasdaq: SLP) has announced a strategic restructuring of its business units and leadership to support future growth following recent acquisitions. The company is forming two new business units: Adaptive Learning & Insights and Medical Communications, while transitioning Regulatory Strategies into a Center of Excellence. This reorganization aims to enhance customer engagement, accelerate cross-selling opportunities, and maximize growth potential.

Key leadership changes include:

• Steven Chang promoted to President, Quantitative Systems Pharmacology
• Jenna Rouse promoted to President of Adaptive Learning & Insights
• Murry Alper promoted to President of Medical Communications
• Sandra Suarez-Sharp transitioning to President, Regulatory Strategies Center of Excellence

Simulations Plus (Nasdaq: SLP) has released DILIsym® version X (DSX), an updated quantitative systems toxicology (QST) platform. DSX is designed to predict drug-induced liver injury (DILI) risks, supporting critical drug development decisions. The software features:

- Enhanced processing speed
- Improved user interface
- Command line and graphical interface options
- Licensing for scale-up on local or cloud clusters
- Four new exemplar compounds
- Two new simulated populations

DSX aims to help researchers identify potential DILI risks, design mitigating dosing strategies, and make faster go/no-go decisions. This can lead to more efficient drug development processes, potentially reducing costly failed clinical trials and accelerating safe drug delivery to patients.

Simulations Plus (Nasdaq: SLP) has released version 12.0 of ADMET Predictor® (AP12), its flagship machine learning platform for drug discovery and optimization. Key enhancements include:

1. Enhanced models with 30% larger training sets for improved predictive accuracy
2. Advanced High-Throughput Pharmacokinetics (HTPK) options
3. Artificial Intelligence-Driven Drug Design (AIDD) with 3D shape matching and tissue sensitivities
4. New Drug-Induced Liver Injury (DILI) module for early drug development
5. Boosted ANN Regression Models and 37 new descriptors in ADMET Modeler™
6. Improved usability and informatics features

These upgrades aim to enhance prediction confidence, workflow integration, and automation capabilities for drug discovery research.

Simulations Plus (Nasdaq: SLP), a leader in biosimulation and medical communications for the biopharma industry, announced CEO Shawn O’Connor's participation in KeyBanc Capital Markets’ 25th Annual Technology Leadership Forum on August 5, 2024, in Vail, Colorado. O’Connor will host one-on-one meetings and participate in a panel discussion titled ‘AI and Digital Solutions for Drug Discovery’ before engaging in a 25-minute Fireside Chat at 1:30 p.m. MDT (3:30 p.m. EDT). A live audio webcast of the Fireside Chat will be accessible via a provided link and on the Investors page of the Simulations Plus website, where it will be available for replay for 90 days.

Simulations Plus (Nasdaq: SLP), a prominent provider of biosimulation and medical communications solutions for the biopharma industry, has announced a new research project with the International Collaboration on Cosmetics Safety (ICCS). The project aims to define best practices for using novel physiologically-based kinetic (PBK) modeling strategies to support animal-free safety assessments of new chemicals. Simulations Plus was selected through a competitive bidding process to establish workflows for PBK modeling based on pharmacokinetic analogs. The collaboration will involve reviewing ICCS data, building PBK models, and applying these in virtual populations to predict chemical exposure. Results and best practices will be published, potentially advancing non-animal testing methods in the cosmetics industry.

Simulations Plus (Nasdaq: SLP) reported its Q3 fiscal 2024 results, showing a 14% increase in total revenue to $18.5M. Software revenue rose 12% to $11.9M, and services revenue grew 18% to $6.6M. Despite consistent gross profit at $13.3M, net income declined to $3.1M from $4.0M, with diluted EPS dropping to $0.15 from $0.20. Adjusted diluted EPS, excluding acquisition costs, was $0.19. For the first nine months of fiscal 2024, total revenue increased 17% to $51.3M, with a net income of $9.1M and diluted EPS of $0.45. The company maintains FY2024 revenue guidance of $69-72M and updates EPS guidance.

The recent acquisition of Pro-ficiency is progressing as planned, and the newly formed Clinical Simulations and Medical Communications unit is expected to contribute $3M in FY2024. The company will discontinue its quarterly dividend to reallocate funds towards growth initiatives. A final dividend of $0.06 per share will be paid on August 5, 2024, to shareholders of record as of July 29, 2024.

Simulations Plus (Nasdaq: SLP), a leader in biosimulation and medical communications for the biopharma sector, announced CEO Shawn O’Connor's participation in the Morgan Stanley 3rd Annual Life Sciences AI Summit. The summit is scheduled for June 26, 2024, at Morgan Stanley's HQ in New York City. O’Connor will engage in a panel discussion titled “Transforming Research – Optimizing from Lab to Trial” at 2:10 p.m. EDT, followed by one-on-one meetings with investors. The event emphasizes AI-driven changes in the biopharma industry, featuring key companies at the juncture of life sciences and technology innovation.